Although at least three other activating missense substitutions have been described in SRD5A2 (p.Val3Ile, p.Phe118Leu, and p.Ala248Val), these were identified from microdissected prostate adenocarcinoma samples and were found to be somatic mutations (Makridakis et al. 2004). This evidence concerns the gene SRD5A2 and prostate adenocarcinoma.